Symmetrical dimethylarginine
metaboliteSymmetrical dimethylarginine elevation impairs endothelial NO production and marks myocardial remodeling after acute MI.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencemedium
RationaleSDMA inhibits endothelial nitric oxide synthase; remodeling marker post-STEMI.
Also acts inEndothelial activation/erosion, Myocardial injury
Druggability
Not assessed (no mapped human gene target).
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(1)
- Metabolomic Approach in STEMI-Patients Undergoing Left Ventricular Remodeling.International journal of molecular sciences · 2019 · PMID 30642070 · doi